Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:1532909rdf:typepubmed:Citationlld:pubmed
pubmed-article:1532909lifeskim:mentionsumls-concept:C0205145lld:lifeskim
pubmed-article:1532909lifeskim:mentionsumls-concept:C0003250lld:lifeskim
pubmed-article:1532909lifeskim:mentionsumls-concept:C0040549lld:lifeskim
pubmed-article:1532909lifeskim:mentionsumls-concept:C1704632lld:lifeskim
pubmed-article:1532909lifeskim:mentionsumls-concept:C0871261lld:lifeskim
pubmed-article:1532909lifeskim:mentionsumls-concept:C0439851lld:lifeskim
pubmed-article:1532909lifeskim:mentionsumls-concept:C2911692lld:lifeskim
pubmed-article:1532909lifeskim:mentionsumls-concept:C1706817lld:lifeskim
pubmed-article:1532909lifeskim:mentionsumls-concept:C1440058lld:lifeskim
pubmed-article:1532909lifeskim:mentionsumls-concept:C2246527lld:lifeskim
pubmed-article:1532909lifeskim:mentionsumls-concept:C1552596lld:lifeskim
pubmed-article:1532909lifeskim:mentionsumls-concept:C1947931lld:lifeskim
pubmed-article:1532909lifeskim:mentionsumls-concept:C0684162lld:lifeskim
pubmed-article:1532909pubmed:issue4lld:pubmed
pubmed-article:1532909pubmed:dateCreated1992-5-20lld:pubmed
pubmed-article:1532909pubmed:abstractTextSerotherapy, an approach currently used to protect humans against animal bites or stings, is often too specific. To broaden antiserum paraspecificity, use of antibodies directed against areas shared by all members of a toxin family was previously proposed. MST2 is a mAb that recognizes all long-chain curaremimetic toxins (Charpentier et al. (1990) J. Mol. Recog. 3, 74-81). It binds to toxin residues that make contact with the toxin's target, e.g., the nicotinic acetylcholine receptor (AcChoR). We now show that MST2 also recognizes (-) nicotine, an agonist of AcChoR. Binding properties of MST2 therefore mimick, at least partially, binding properties of AcChoR. Injection in rabbits of MST2 mixed with adjuvant, elicited anti-idiotypic (anti-Id) antibodies that inhibited binding of the toxin to AcChoR. A proportion of these anti-Id antibodies specifically bound AcChoR and thereby mimicked the toxin. Furthermore, rabbits immunized with MST2 elicited auto-anti-anti-Id antibodies capable of binding the toxin. Our data provide a molecular explanation for the previously reported signs of myasthenia gravis as triggered by antibodies raised against cholinergic antagonists. Implications in the design of antisera to toxic proteins are discussed.lld:pubmed
pubmed-article:1532909pubmed:languageenglld:pubmed
pubmed-article:1532909pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1532909pubmed:citationSubsetIMlld:pubmed
pubmed-article:1532909pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1532909pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1532909pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1532909pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1532909pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1532909pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1532909pubmed:statusMEDLINElld:pubmed
pubmed-article:1532909pubmed:monthAprlld:pubmed
pubmed-article:1532909pubmed:issn0006-3002lld:pubmed
pubmed-article:1532909pubmed:authorpubmed-author:MénezAAlld:pubmed
pubmed-article:1532909pubmed:authorpubmed-author:CharpentierIIlld:pubmed
pubmed-article:1532909pubmed:authorpubmed-author:LéonettiMMlld:pubmed
pubmed-article:1532909pubmed:authorpubmed-author:PillerBBlld:pubmed
pubmed-article:1532909pubmed:issnTypePrintlld:pubmed
pubmed-article:1532909pubmed:day14lld:pubmed
pubmed-article:1532909pubmed:volume1138lld:pubmed
pubmed-article:1532909pubmed:ownerNLMlld:pubmed
pubmed-article:1532909pubmed:authorsCompleteYlld:pubmed
pubmed-article:1532909pubmed:pagination282-9lld:pubmed
pubmed-article:1532909pubmed:dateRevised2007-11-15lld:pubmed
pubmed-article:1532909pubmed:meshHeadingpubmed-meshheading:1532909-...lld:pubmed
pubmed-article:1532909pubmed:meshHeadingpubmed-meshheading:1532909-...lld:pubmed
pubmed-article:1532909pubmed:meshHeadingpubmed-meshheading:1532909-...lld:pubmed
pubmed-article:1532909pubmed:meshHeadingpubmed-meshheading:1532909-...lld:pubmed
pubmed-article:1532909pubmed:meshHeadingpubmed-meshheading:1532909-...lld:pubmed
pubmed-article:1532909pubmed:meshHeadingpubmed-meshheading:1532909-...lld:pubmed
pubmed-article:1532909pubmed:meshHeadingpubmed-meshheading:1532909-...lld:pubmed
pubmed-article:1532909pubmed:meshHeadingpubmed-meshheading:1532909-...lld:pubmed
pubmed-article:1532909pubmed:meshHeadingpubmed-meshheading:1532909-...lld:pubmed
pubmed-article:1532909pubmed:meshHeadingpubmed-meshheading:1532909-...lld:pubmed
pubmed-article:1532909pubmed:meshHeadingpubmed-meshheading:1532909-...lld:pubmed
pubmed-article:1532909pubmed:meshHeadingpubmed-meshheading:1532909-...lld:pubmed
pubmed-article:1532909pubmed:meshHeadingpubmed-meshheading:1532909-...lld:pubmed
pubmed-article:1532909pubmed:year1992lld:pubmed
pubmed-article:1532909pubmed:articleTitleAnti-idiotypic and anti-anti-idiotypic responses to a monoclonal antibody directed to the acetylcholine receptor binding site of curaremimetic toxins.lld:pubmed
pubmed-article:1532909pubmed:affiliationDépartement d'Ingenierie et d'Etudes des Protéines CE Saclay, Gif-sur-Yvette, France.lld:pubmed
pubmed-article:1532909pubmed:publicationTypeJournal Articlelld:pubmed